CAPN1 autosomal recessive complex spastic paraplegia is a rare inherited nerve disorder. It mainly damages the long movement pathways that run from the brain to the spinal cord (the corticospinal tracts). People develop stiff, tight, and weak leg muscles (spastic paraplegia). Many people also have poor balance and shaky movements (cerebellar ataxia), slurred speech, and sometimes mild sensory nerve damage. The problem comes from harmful changes (pathogenic variants) in the CAPN1 gene. This gene makes calpain-1, a calcium-activated enzyme (a cysteine protease) that helps brain cells keep their connections healthy and helps axons grow and stay strong. When calpain-1 does not work, synapses do not remodel normally, axons are not maintained well, and parts of the brain that control movement and balance can slowly lose function. Cell+2Cell+2

CAPN1-related spastic paraplegia (SPG76) is a rare inherited nerve disorder where both copies of the CAPN1 gene are changed (autosomal recessive). CAPN1 makes calpain-1, a calcium-activated protein that helps nerve cells keep their connections healthy. When it does not work well, the long wires (axons) that carry movement signals to the legs slowly get sick. People usually develop stiff legs (spasticity), leg weakness, walking trouble, and often “complex” features such as balance problems (ataxia), slurred speech (dysarthria), or feeling changes. Symptoms often start in the teens to adulthood and get worse slowly over years. Life span is usually near normal, but daily function may be reduced without therapy. There is no disease-curing drug yet; care focuses on rehabilitation, spasticity control, fall prevention, bladder care, and mood/sleep support. orpha.net+2Wiley Online Library+2

The condition is autosomal recessive. That means a person gets one non-working copy of the gene from each parent. Parents are usually healthy carriers. The illness can begin in childhood or adulthood. Symptoms usually get worse slowly over years. Some people show only spastic paraplegia. Others have a “complex” picture with ataxia, speech problems, eye movement issues, or mild peripheral neuropathy. Cell+2Wiley Online Library+2

Other names

This disorder appears in the medical literature under several names. Knowing them helps you find information across sources:

• Spastic Paraplegia 76 (SPG76) – the numbered subtype within the large HSP family. Cell

• CAPN1-related hereditary spastic paraplegia – highlights the gene. Wiley Online Library

• Calpain-1–related spastic ataxia – used when ataxia is prominent. Frontiers

• CAPN1-associated neurodegeneration – a broader phrase used in reviews and case series. jmedcasereportsimages.org

Types

Doctors often group HSP into “pure” and “complicated (complex)” forms. CAPN1 disease can present as either:

1. Pure type – leg stiffness, leg weakness, brisk reflexes, and walking difficulty without other major features. This is less common but reported. PMC
2. Complex (complicated) type – the classic CAPN1 pattern. Spastic paraplegia is joined by one or more of these: ataxia, dysarthria, eye movement abnormalities, mild peripheral neuropathy, skeletal issues, bladder symptoms, or rarely mood/behavior changes. ScienceDirect+1

Causes

Because this condition is genetic, all true causes relate to how variants disrupt calpain-1 and the systems that depend on it. Below, each item is a short, plain-language explanation of a distinct disease-driving mechanism or pathway, with evidence where available.

1. Biallelic CAPN1 loss-of-function variants
   The core cause. Two harmful variants (one from each parent) inactivate calpain-1 and produce SPG76. Cell

2. Nonsense or frameshift changes
   Variants that create a premature stop codon or shift the reading frame can truncate calpain-1 and abolish its activity. Cell

3. Missense variants in key domains
   A single amino-acid change in the catalytic or calcium-binding regions can reduce enzyme activity or calcium sensitivity. Cell

4. Splice-site variants
   Errors at intron–exon junctions can mis-splice CAPN1 RNA and remove essential parts of the protein. Cell

5. Compound heterozygosity
   Two different CAPN1 variants (one on each allele) together cause disease, even when each alone would not. Cell

6. Homozygosity in consanguineous families
   When parents are related, both may carry the same variant, raising the chance that a child inherits two copies. Clinical series report such families. PubMed

7. Loss of calpain-1–mediated synaptic plasticity
   Calpain-1 supports synapse remodeling. Loss disrupts plasticity and motor network function. Cell

8. Impaired axon maturation and maintenance
   Calpain-1 helps axons develop and stay healthy. Defects promote corticospinal tract degeneration. Cell

9. Cerebellar vulnerability
   Animal and human data link calpain-1 deficiency to cerebellar dysfunction and ataxia. neurology.org

10. Disturbed calcium-dependent proteolysis
    Calpain-1 is activated by calcium. Faulty activation means key neuronal proteins are not processed correctly. geneglobe.qiagen.com

11. Faulty interaction with the small regulatory subunit (CAPNS1)
    Calpains work as heterodimers. CAPN1 variants may impair complex formation or stability. geneglobe.qiagen.com

12. Protein quality-control stress
    Misfolded calpain-1 or downstream protein buildup can stress neurons and accelerate degeneration (inference from calpain biology and HSP mechanisms). MDPI

13. White-matter tract degeneration
    Long motor pathways slowly degenerate when axon maintenance is impaired. MDPI

14. Purkinje cell dysfunction
    These cerebellar neurons are essential for coordination; they appear sensitive to calpain-1 loss. neurology.org

15. Secondary peripheral axonal injury
    Some patients show sensory axonal neuropathy, implying distal axon stress beyond the CNS. PreventionGenetics

16. Genetic modifiers
    Other genes may shape severity or add features (e.g., more ataxia vs. “purer” HSP), as seen across HSP families. MDPI

17. Variant-specific residual activity
    Different variants leave different amounts of enzyme function. Residual activity often predicts “pure” vs “complex” pictures. PMC

18. Age-related cumulative damage
    Because repair and plasticity are reduced, everyday wear on long tracts adds up over years, so symptoms slowly progress. MDPI

19. Brain network maladaptation
    When circuits cannot remodel properly, compensatory movements fail and spasticity/ataxia worsen (mechanistic inference from calpain-1 role in plasticity). Cell

20. Large deletions or complex rearrangements in CAPN1
    Less common, but structural variants that remove exons or alter gene structure can inactivate calpain-1. Cell

Symptoms

Not everyone has all symptoms. The mix and timing vary even within families.

1. Stiff, tight legs (spasticity) – the hallmark. Muscles resist movement and feel “clenched.” Walking becomes effortful. Cell

2. Leg weakness – especially hip flexors and ankle dorsiflexors, which increases tripping. Cell

3. Brisk reflexes and Babinski signs – toe goes up when the sole is stroked; reflexes “jump.” Cell

4. Scissoring or stiff-leg gait – legs cross or stay straight, making turns hard. MDPI

5. Balance problems – from cerebellar ataxia; standing and walking feel unsteady. BioMed Central

6. Clumsy, shaky limb movements – intention tremor or dysmetria when reaching for objects. BioMed Central

7. Slurred or scanning speech (dysarthria) – words sound slow or choppy when ataxia is present. PreventionGenetics

8. Upper-limb involvement – stiffness or poor fine movements in the arms in some people. PreventionGenetics

9. Sensory symptoms – mild numbness or tingling from sensory axonal neuropathy in a subset. PreventionGenetics

10. Bladder urgency or frequency – common in many HSPs; can appear in SPG76. MalaCards

11. Eye movement problems – saccadic or smooth pursuit abnormalities are reported in some cases. ScienceDirect

12. Foot deformities – such as high arches or hammer toes in long-standing disease (seen across HSP). ScienceDirect

13. Fatigue – walking with spasticity and poor balance costs more energy. MDPI

14. Cramps or spasms – painful tightening in calves or thighs. MDPI

15. Mood or behavioral change in rare cases – occasional reports mention emotional symptoms or behavioral disturbance. PubMed

Diagnostic tests

Doctors diagnose SPG76 by combining clinical signs, family history, and genetic testing. Other tests help document features and rule out look-alikes.

A) Physical examination (bedside neurologic exam)

1. Muscle tone check
   The doctor moves your legs and feels resistance that increases with speed. This pattern fits spasticity. It confirms corticospinal tract involvement. MDPI

2. Reflex testing
   Tendon taps at the knee and ankle are brisk; ankle clonus may appear. This points to an upper motor neuron problem. MDPI

3. Plantar response (Babinski)
   Up-going big toe supports an upper motor neuron disorder like HSP. MDPI

4. Gait observation
   Doctors watch for stiff-leg or scissoring gait and short steps. The exam documents severity and fall risk. MDPI

5. Coordination testing
   Finger-to-nose and heel-to-shin show past-pointing or shaky movement if ataxia is present, a common CAPN1 feature. BioMed Central

6. Speech and cranial nerve exam
   A slow, scanning voice suggests cerebellar dysarthria; eye-movement testing may show saccadic or pursuit abnormalities in some. ScienceDirect

7. Sensation testing
   Pin, vibration, and position sense can be slightly reduced if there is a mild sensory axonal neuropathy. PreventionGenetics

B) Manual or bedside functional tests

8. Timed 10-meter walk
   Measures walking speed on a flat path. Slowing over time marks progression and guides therapy. (Standard HSP functional metric.) MDPI

9. Tandem gait (heel-to-toe) test
   Ataxia and spasticity make straight-line heel-to-toe walking hard. Failure supports a complex form. BioMed Central

10. Romberg test
    Standing with feet together, then eyes closed. Swaying suggests proprioceptive or cerebellar issues seen in some patients. MDPI

11. Finger-tapping or peg tests
    Quick, repetitive hand tasks show upper-limb involvement or ataxia beyond the legs. MDPI

12. Modified Ashworth Scale for spasticity
    A hands-on rating of muscle resistance helps track response to therapy. (Used widely across spasticity disorders.) MDPI

13. Functional reach or balance scales
    Simple reach or stance tasks quantify balance limits and fall risk in complex forms. MDPI

C) Laboratory and pathological tests

14. Targeted CAPN1 gene sequencing
    Looks directly for disease-causing variants in CAPN1. This is the key confirmatory test when clinical features fit SPG76. PreventionGenetics

15. Hereditary spastic paraplegia multigene panel
    Screens many HSP genes at once because dozens can mimic each other. Useful when the picture is unclear. MDPI

16. Whole-exome or whole-genome sequencing
    Broad testing can find novel or rare CAPN1 variants, especially in small families or when panels are negative. (First CAPN1 discoveries used exome sequencing.) Cell

17. Copy-number analysis (e.g., exon-level CNV)
    Checks for missing or extra CAPN1 exons that sequencing can miss. Helps detect rare deletions/duplications. Cell

18. Basic metabolic and vitamin labs (rule-out tests)
    B12, copper, thyroid, and other screens exclude treatable mimics of spasticity/ataxia. These are standard in HSP work-ups. MDPI

19. Creatine kinase (CK)
    Usually normal or mildly raised. It helps exclude primary muscle disease when weakness is present. MDPI

20. (Rarely) nerve or skin biopsy for research
    Occasionally used in studies to investigate axonal pathology; not routine for diagnosis once genetics are clear. Lippincott Journals

D) Electrodiagnostic tests

21. Nerve conduction studies (NCS)
    Can show sensory axonal neuropathy in a subset of patients; motor studies are often near normal. Findings support a complex phenotype. PreventionGenetics

22. Electromyography (EMG)
    May be normal or show mild chronic neurogenic changes. Used mainly to rule out other motor neuron or muscle disorders. MDPI

23. Somatosensory evoked potentials (SSEPs)
    Test the dorsal columns and central sensory pathways. Delays suggest long-tract involvement beyond the corticospinal tracts. MDPI

24. Motor evoked potentials (MEPs)
    Assess corticospinal conduction. Prolonged central motor conduction times support an upper motor neuron disorder like HSP. MDPI

E) Imaging tests

25. Brain MRI
    Many patients have normal scans, but some show mild to moderate cerebellar atrophy that matches the ataxia part of the syndrome. PreventionGenetics+1

26. Spinal MRI
    Often normal, but rules out compressive or inflammatory causes of spastic paraparesis that can mimic HSP. MDPI

27. MRI with diffusion or tractography (research/advanced use)
    May highlight subtle long-tract changes in the brain’s motor pathways, supporting the clinical picture. MDPI

28. Follow-up MRI over time
    Helps document whether cerebellar volume or other features change as symptoms progress. Frontiers

29. Brainstem and cerebellar sequences (fine cuts)
    Targeted imaging improves detection of cerebellar changes when speech and balance are clearly affected. Frontiers

30. Ultrasound of bladder (selective)
    Used if bladder symptoms are significant, to check emptying and guide management; supportive rather than diagnostic for SPG76. (General HSP practice.) MDPI

Non-pharmacological treatments (therapies and “other”)

1. Individualized Physiotherapy Program
   Description: A structured plan built by a neuro-physiotherapist to reduce stiffness, keep joints moving, and train safer walking. It mixes gentle daily stretching, progressive strengthening, posture drills, balance practice, and gait training. Sessions typically occur 2–3 times weekly at first, then taper to a maintain-at-home plan. Teaching caregivers how to help safely is vital. The therapist also screens braces, canes, or walkers and monitors fatigue and pain. Goals are set around what matters most (e.g., stairs, bathing, work). Outcome measures like Timed Up & Go and 10-m walk track progress. Early and continuous PT slows secondary problems like contractures (fixed joint tightness). Purpose: maintain mobility, cut falls, and delay complications. Mechanism: stretching reduces muscle-tendon stiffness; strengthening improves motor unit recruitment; repetitive gait drills help the nervous system relearn patterns (neuroplasticity). SAGE Journals+1

2. Daily Stretching & Range-of-Motion (ROM)
   Description: Gentle, slow stretches for hips, hamstrings, calves, and hip adductors held ~30–60 seconds, 1–2 sets/day. Use heat or shower warm-up to relax muscles first. Add prolonged positioning (e.g., night splints) if needed. Purpose: prevent contractures and reduce painful spasms. Mechanism: lengthens muscle-tendon units, decreases reflex excitability, and improves joint biomechanics for gait. NICE

3. Progressive Resistance Training
   Description: 2–3 days/week of low-to-moderate intensity strengthening for hip extensors, abductors, knee flexors/extensors, and dorsiflexors with bands or machines; emphasize quality over speed. Purpose: counter weakness and improve push-off/foot clearance. Mechanism: increases muscle fiber recruitment and improves functional reserve to fight fatigue. SAGE Journals

4. Task-specific Gait Training (Overground)
   Description: Repeated practice of real-life walking tasks—starts/stops, turns, stairs, uneven ground—with cues and video feedback. Purpose: normalize gait pattern and improve community walking. Mechanism: motor learning via high-repetition, context-specific practice. SAGE Journals

5. Body-Weight–Supported Treadmill Training (BWSTT)
   Description: Harness unloads part of body weight while walking on a treadmill, allowing longer, safer practice with therapist cueing. Typical programs: 20–30 minutes, 3–5 days/week for 4–8 weeks. Purpose: boost balance, endurance, and gait kinematics while reducing fall risk during training. Mechanism: intensive stepping practice enhances spinal and cortical locomotor circuits. Frontiers+1

6. Functional Electrical Stimulation (FES) for Foot-Drop
   Description: A small stimulator activates the peroneal nerve during swing phase to lift the foot and avoid tripping. It can be used daily during walking practice and at home. Purpose: improve walking speed and safety; sometimes reduces effort. Mechanism: timed electrical pulses create ankle dorsiflexion, improving toe clearance and symmetry. PubMed+1

7. Aquatic Therapy (Hydrotherapy)
   Description: Supervised pool sessions use buoyancy and water resistance to allow easier movement with less fall risk. Sessions include walking, balance drills, gentle strengthening, and trunk rotation. Purpose: lower spasticity, improve range, and build endurance with less pain. Mechanism: warm water reduces reflex hyperactivity; hydrostatic pressure and resistance train muscles while protecting joints. PubMed+1

8. Balance & Vestibular Therapy
   Description: For those with ataxia, graded balance tasks (static to dynamic), head-eye coordination drills, and sensory reweighting. Purpose: reduce falls and dizziness. Mechanism: cerebellar-driven adaptation through repeated challenge in safe conditions. Frontiers

9. Occupational Therapy (OT)
   Description: Energy-saving strategies, task simplification, home/work modifications, bathroom safety, adaptive tools for dressing, cooking, writing, and computer use. Purpose: maintain independence in daily living and reduce caregiver load. Mechanism: compensates for motor deficits by redesigning tasks and environments. Genomics Education Programme

10. Speech-Language Therapy (if dysarthria)
    Description: Breath-voice control, pacing, articulation, and communication tech (apps) if speech becomes unclear. Purpose: clearer, less tiring communication. Mechanism: targeted motor speech drills improve coordination and intelligibility. Frontiers

11. Orthoses (AFOs, night splints)
    Description: Ankle-foot orthoses for foot-drop; plantarflexion stop AFOs reduce knee hyperextension; night splints maintain length. Purpose: safer gait and contracture prevention. Mechanism: aligns joints and controls excessive tone-driven movements. SAGE Journals

12. Canes, Crutches, Walkers (Assistive Mobility)
    Description: Right device, correct height, and gait pattern instruction reduce falls and increase community mobility. Purpose: fall prevention and confidence. Mechanism: wider base and load-sharing reduce demands on spastic muscles. SAGE Journals

13. Botulinum Toxin-Guided Therapy Program
    Description: While botulinum toxin is a medicine (below), it works best as part of a therapy program: injections into focal overactive muscles followed by intensive stretching/strengthening and casting if needed. Purpose: reduce focal spasticity that blocks function (e.g., scissoring or equinus). Mechanism: blocks acetylcholine at the neuromuscular junction to relax targeted muscles; therapy then retrains movement. rcp.ac.uk+1

14. Casting/Serial Casting
    Description: Short-term casts after injections or stretching to hold lengthened muscle position (e.g., calf). Purpose: increase ankle dorsiflexion and reduce toe-walking. Mechanism: low-load prolonged stretch remodels muscle-tendon unit. rcp.ac.uk

15. Pain & Spasm Self-Management (heat, pacing, sleep)
    Description: Warm showers, local heat, gentle massage, mindful pacing of activities, sleep hygiene. Purpose: fewer spasms and better stamina. Mechanism: warmth lowers reflexes; pacing reduces fatigue-triggered stiffness. SAGE Journals

16. Bladder Training & Pelvic Floor Therapy
    Description: Timed voiding, urge-suppression drills, pelvic floor exercises; coordinate with urology. Purpose: reduce urgency and leakage that often accompany UMN syndromes. Mechanism: neuromuscular retraining of pelvic floor and behavioral control of detrusor triggers. Medscape

17. Fall-Proofing the Home
    Description: Remove loose rugs, add grab bars/rails, improve lighting, non-slip footwear, shower chair. Purpose: fewer injuries. Mechanism: environmental risk reduction. SAGE Journals

18. Mental Health & Fatigue Management
    Description: Screen and treat anxiety/depression; consider CBT, peer support; schedule activity-rest cycles. Purpose: better quality of life and adherence to therapy. Mechanism: reduces central fatigue and improves motivation. Frontiers

19. Vitamin D & Bone Health Plan (with doctor)
    Description: Check vitamin D level; combine with safe sunlight, diet, and weight-bearing as able. Purpose: protect against osteoporosis and fractures from falls. Mechanism: vitamin D supports muscle and bone function. PubMed+1

20. Community Participation & Vocational Rehab
    Description: Work or study adaptations, transport planning, disability services, and social engagement. Purpose: maintain roles and mental wellbeing. Mechanism: reduces isolation and supports long-term function. Genomics Education Programme

---

Drug treatments

Important: There is no approved disease-modifying drug for CAPN1-HSP yet. Medicines below target spasticity, cramps, neuropathic pain, bladder urgency, and gait safety. Doses are typical U.S. label ranges—clinicians personalize and monitor interactions/contraindications.

1. Baclofen (oral) – Class: GABA-B agonist antispastic. Dose/Time: start 5 mg 3×/day, titrate; usual 40–80 mg/day divided. Purpose: reduce generalized spasticity and cramps. Mechanism: reduces excitatory neurotransmission in spinal cord to relax muscles. Side effects: sleepiness, dizziness, weakness; taper slowly to avoid withdrawal. NICE

2. Baclofen (intrathecal, ITB pump: Lioresal® Intrathecal) – Class: GABA-B agonist delivered to CSF. Dose: screening bolus then implanted pump with programmable micro-doses. Purpose: severe refractory spasticity when oral drugs fail. Mechanism: high spinal concentrations with fewer systemic effects. Side effects: overdose/withdrawal risks; pump/catheter complications—specialist care needed. PubMed

3. Tizanidine – Class: α2-adrenergic agonist antispastic. Dose: start 2 mg up to every 6–8 h; titrate (max often 36 mg/day). Purpose: reduce tone with less muscle weakness than some agents. Mechanism: inhibits polysynaptic spinal reflexes. Side effects: sedation, dry mouth, low blood pressure; watch liver tests and interactions (CYP1A2). FDA Access Data

4. Dantrolene – Class: peripheral muscle relaxant. Dose: start 25 mg/day; titrate to effect (common 25–100 mg 3–4×/day). Purpose: reduce severe spasticity when others fail. Mechanism: reduces calcium release from sarcoplasmic reticulum. Side effects: fatigue, weakness; rare hepatotoxicity—monitor LFTs. FDA Access Data

5. Diazepam – Class: benzodiazepine. Dose: small bedtime or divided doses. Purpose: short-term relief of spasms, nocturnal cramps, anxiety. Mechanism: GABA-A modulation. Side effects: sedation, dependence; use cautiously. FDA Access Data

6. Clonazepam – Class: benzodiazepine. Dose: 0.25–0.5 mg at night or divided; titrate. Purpose: spasm/tremor relief and sleep. Mechanism: GABA-A modulation. Side effects: sedation, imbalance, dependence risk. FDA Access Data

7. OnabotulinumtoxinA (Botox®) – Class: neuromuscular blocking biologic. Dose: focal injections by trained clinician every ~12 weeks (dose by muscle). Purpose: treat focal spasticity (e.g., calf/adductor overactivity). Mechanism: blocks acetylcholine release, reducing overactive muscles while preserving others. Side effects: local weakness, pain, rare spread-of-toxin effects. Works best combined with therapy and stretching. FDA Access Data+1

8. Gabapentin – Class: anticonvulsant/neuropathic pain agent. Dose: titrate from 100–300 mg at night; common 300–900 mg 3×/day. Purpose: neuropathic pain, paresthesias, sometimes spasm-related discomfort. Mechanism: α2δ calcium channel modulation. Side effects: sedation, dizziness; adjust in renal disease. FDA Access Data

9. Pregabalin – Class: α2δ calcium channel modulator. Dose: 50–100 mg 2–3×/day (adjust renal). Purpose: neuropathic pain and sleep improvement. Mechanism: reduces excitatory neurotransmitter release. Side effects: dizziness, weight gain, edema. FDA Access Data

10. Duloxetine – Class: SNRI. Dose: 30–60 mg/day. Purpose: neuropathic pain and mood/anxiety symptoms common in chronic neurologic disease. Mechanism: increases serotonin/norepinephrine in pain pathways. Side effects: nausea, dry mouth, BP changes. FDA Access Data

11. Amitriptyline – Class: tricyclic antidepressant. Dose: 10–25 mg at night; titrate. Purpose: neuropathic pain, sleep. Mechanism: noradrenergic/serotonergic modulation and sodium channel effects. Side effects: dry mouth, constipation, QT risk—use cautiously. FDA Access Data

12. Oxybutynin (oral or ER) – Class: antimuscarinic for overactive bladder. Dose: ER 5–10 mg daily; titrate. Purpose: urgency, frequency, leakage. Mechanism: reduces involuntary bladder contractions. Side effects: dry mouth, constipation, blurry vision. FDA Access Data

13. Solifenacin (VESIcare®) – Class: antimuscarinic. Dose: 5 mg daily; can increase to 10 mg if tolerated. Purpose: overactive bladder symptoms. Mechanism: M3 receptor antagonism in detrusor muscle. Side effects: anticholinergic effects; adjust in renal/hepatic impairment. FDA Access Data+1

14. Tolterodine (Detrol LA®) – Class: antimuscarinic. Dose: LA 4 mg daily; adjust per tolerance/renal/hepatic function. Purpose: urgency/frequency. Mechanism: competitive muscarinic blockade. Side effects: dry mouth, constipation; QT caution. FDA Access Data

15. Mirabegron (Myrbetriq®) – Class: β3-adrenergic agonist. Dose: 25 mg daily, may increase to 50 mg. Purpose: overactive bladder when anticholinergics are not tolerated. Mechanism: relaxes detrusor muscle during storage. Side effects: ↑BP, urinary retention risk in obstruction. FDA Access Data

16. Dalfampridine (Ampyra®) – Class: potassium-channel blocker. Dose: 10 mg twice daily (do not crush; avoid if seizures or CrCl ≤50). Purpose: improves walking speed in MS; sometimes used off-label to aid gait in other upper-motor-neuron disorders after careful risk review. Mechanism: prolongs action potentials in demyelinated axons to enhance conduction. Side effects: seizures with overdose, insomnia, dizziness. FDA Access Data

17. Topical agents for focal pain (e.g., lidocaine patch) – Class: local anesthetic. Use: apply to painful areas (not to broken skin). Purpose: reduce localized neuropathic pain without systemic sedation. Mechanism: sodium channel blockade in skin nerves. Side effects: local irritation; limited systemic exposure. (Label examples: FDA Lidocaine patch 5%.) NICE

18. Cyclobenzaprine (short term for acute spasm flare) – Class: centrally acting muscle relaxant. Dose: 5–10 mg at night. Purpose: transient relief during painful spasm spikes; not for chronic spasticity. Mechanism: brainstem modulation. Side effects: sedation, anticholinergic effects. (FDA label available; use cautiously.) NICE

19. Analgesics (acetaminophen/NSAIDs as needed) – Class: pain relievers. Purpose: musculoskeletal pain from overuse or falls; use the lowest effective dose and protect stomach/kidneys. Mechanism: central prostaglandin (APAP) or COX inhibition (NSAIDs). Side effects: liver risk (APAP), GI/kidney/cardiovascular risks (NSAIDs). (FDA labels for OTC analgesics.) NICE

20. Antidepressants/Anxiolytics when indicated (careful selection) – Class: SSRIs/SNRIs/others. Purpose: treat depression/anxiety common in chronic neurologic illness; improves participation in rehab. Mechanism: neurotransmitter modulation. Side effects: class-dependent; coordinate with neurology for interactions with spasticity meds. (FDA labeling per drug). NICE

Why these drugs? Spasticity care is guided by national guidelines and expert statements, which endorse oral antispastics, focal botulinum toxin, and intrathecal baclofen as core tools, always tied to a rehab plan. Bladder and neuropathic pain drugs follow their FDA labels but are applied to symptoms that often come with upper motor neuron syndromes. rcp.ac.uk+2rcp.ac.uk+2

---

Dietary molecular supplements

1. Vitamin D
   What & why (≈150 words): Many people with neurologic conditions have low vitamin D, which links to muscle weakness and falls. Correcting deficiency can support muscle function and bone health, especially if activity is limited. Typical repletion uses 800–2000 IU/day (or clinician-guided higher doses if levels are very low), then maintenance to keep 25-OH vitamin D in the sufficient range. Works best with calcium-adequate diet and safe weight-bearing exercise. Mechanism: vitamin D receptors in muscle influence protein synthesis and calcium handling; systemically it supports calcium/phosphate balance for bone. Evidence: reviews show vitamin D deficiency is associated with poor muscle performance; some meta-analyses suggest strength gains after correction, though results vary and dosing must be individualized. PubMed+1

2. Omega-3 Fatty Acids (EPA/DHA)
   Summary: Omega-3s reduce inflammation in cell membranes and may modestly benefit nerve health, mood, and cardiometabolic risk. Common doses: 1–2 g/day combined EPA+DHA (check anticoagulant interactions). Mechanism: anti-inflammatory lipid mediators (resolvins, protectins) alter immune cell activity and membrane fluidity. Evidence: contemporary reviews and clinical trials in neurologic disease show anti-inflammatory and potential neuroprotective signals, though effects on spasticity directly are uncertain. MDPI+1

3. Coenzyme Q10 (CoQ10)
   Summary: Mitochondrial cofactor supporting cellular energy and antioxidant defense; typical study doses 100–300 mg/day with food. Mechanism: stabilizes electron transport and reduces oxidative stress. Evidence: human studies in neurological conditions show mixed but suggestive benefits on oxidative markers and some cognitive outcomes; it’s generally safe. PMC+1

4. Creatine Monohydrate
   Summary: 3–5 g/day may increase muscle phosphocreatine, improving short-burst strength and training tolerance; loading (20 g/day × 5–7 days) is optional. Mechanism: faster ATP regeneration supports repetitive muscle work. Evidence: RCTs show strength gains in certain neuromuscular disorders; benefits vary by condition and training status. Ensure adequate hydration and discuss kidney history. PMC+1

5. Magnesium (if deficient)
   Summary: Important for nerve-muscle signaling. Routine supplementation for cramps shows limited benefit in most adults unless deficiency exists; typical doses 200–400 mg elemental magnesium/day (watch diarrhea, renal impairment). Mechanism: modulates NMDA receptors and muscle excitability. Evidence: Cochrane and other reviews find little or no meaningful effect on idiopathic muscle cramps overall. Cochrane Library+1

6. Alpha-Lipoic Acid (ALA)
   Summary: Antioxidant used in diabetic neuropathy at 300–600 mg/day; may reduce oxidative stress and burning pain. Mechanism: scavenges reactive oxygen species and improves mitochondrial function. Evidence: benefits established in diabetic neuropathy; extrapolation to HSP-related discomfort is reasonable but unproven. PMC

7. B-Complex (with B12 and Folate if low)
   Summary: Correcting B12/folate deficiency supports myelin and nerve health; dosing depends on labs (e.g., oral B12 1,000 mcg/day). Mechanism: methylation pathways for myelin and neurotransmitters. Evidence: strong for deficiency states; not a treatment for genetic HSP but prevents extra nerve damage. Frontiers

8. Curcumin (standardized)
   Summary: 500–1000 mg/day with piperine may reduce inflammatory signaling; variable absorption. Mechanism: inhibits NF-κB and cytokine pathways. Evidence: broad anti-inflammatory literature; neurologic symptom effects are modest/variable. PMC

9. Resveratrol
   Summary: Polyphenol with antioxidant/anti-inflammatory effects; doses vary (100–500 mg/day). Mechanism: SIRT1 activation and mitochondrial biogenesis. Evidence: mixed human data; theoretical neuroprotection but not disease-modifying proof in HSP. PMC

10. N-Acetylcysteine (NAC)
    Summary: 600–1200 mg/day provides cysteine for glutathione synthesis; sometimes used for oxidative stress. Mechanism: boosts intracellular antioxidant capacity. Evidence: supportive in various oxidative-stress contexts; HSP-specific data lacking. PMC

---

Immunity-booster / regenerative / stem-cell–type” drug concepts

There are no FDA-approved regenerative or stem-cell drugs for CAPN1-HSP. The items below are research areas only; if considered, it should be in a clinical trial.

1. Calpain-2–selective inhibitors (preclinical/early translational) – Target overactive calpain-2 while sparing calpain-1 (which may be neuroprotective). Aim: reduce neurodegeneration and inflammation; human trials are early/limited. PMC+1

2. Pan-calpain inhibitors (legacy molecules like calpeptin) – preclinical – Broad calpain blockade showed mixed results; specificity and brain exposure remain challenges. MDPI+1

3. Gene-based strategies (future concept) – In theory, AAV-mediated gene augmentation or RNA-based fixes for CAPN1 loss-of-function could restore calpain-1; not yet in human trials for SPG76. Wiley Online Library

4. Neurotrophin-pathway modulation – Agents enhancing synaptic plasticity and axonal maintenance are under study broadly; no approved therapy for HSP. Frontiers

5. Cell-based therapies (mesenchymal/hematopoietic stem cells) – Tested in other neurological diseases with variable results; not recommended for HSP outside trials due to uncertain benefit and procedure risks. PMC

6. Neuroinflammation modulators (research context) – Various anti-inflammatory strategies are explored across neurodegeneration; translation to HSP remains unproven. Frontiers

---

Surgeries

1. Intrathecal Baclofen Pump Implantation
   Procedure: Trial dose via spinal injection; if response is good, a small pump is implanted under the abdominal skin with a catheter into the spinal fluid. Pump is refilled every few months. Why: For severe, generalized spasticity that does not respond to pills or botulinum toxin, to improve comfort, ease care, and sometimes gait. Evidence shows reduced spasticity; ongoing follow-up is essential for dose, catheter, and device checks. PMC+1

2. Selective Dorsal Rhizotomy (SDR) (highly selected cases)
   Procedure: Neurosurgeon cuts a portion of sensory rootlets that drive abnormal reflexes. Why: To reduce refractory lower-limb spasticity that blocks function. Adult data are limited but suggest improvement in tone and some functional gains in selected patients; risks include numbness or sensory changes. PMC+1

3. Orthopedic Tendon Lengthening (e.g., hamstrings, Achilles)
   Procedure: Lengthen tight tendons to improve joint motion and reduce crouch or equinus gait; often part of single-event multi-level surgery (SEMLS). Why: Correct fixed contractures after long-standing spasticity to improve gait mechanics, brace fit, and hygiene. Outcomes show gait improvements in select groups; requires rehab. PMC+1

4. Soft-tissue Releases & Transfers
   Procedure: Selective muscle releases or tendon transfers to balance forces around joints (e.g., adductor release to reduce scissoring). Why: Target specific deformities that block standing or walking. SAGE Journals

5. Rhizotomy/Neurolysis Variants (rarely used)
   Procedure: In limited settings, phenol/alcohol neurolysis or modified SDR techniques may be used. Why: For focal refractory tone when other options fail. IMR Press

---

Prevention tips

1. Daily home program of stretching and strengthening to prevent contractures and deconditioning. NICE

2. Fall-proof the home (grab bars, lighting, non-slip shoes). SAGE Journals

3. Use the right mobility aid (cane/AFO/walker) matched by a therapist. SAGE Journals

4. Proactive bladder plan (timed voiding; consider meds if needed). FDA Access Data

5. Bone health (vitamin D sufficiency and weight-bearing within safety). PubMed

6. Energy management (pace, rest scheduling to limit fatigue-triggered spasticity). SAGE Journals

7. Foot-drop solutions (FES or AFO to prevent trips). PubMed

8. Regular therapy check-ins to update the plan as disease changes. SAGE Journals

9. Vaccination & infection prevention (general health guidance to avoid illness-triggered setbacks). NICE

10. Mental health support to maintain participation and consistency. Frontiers

---

When to see a doctor urgently or soon

Urgently: sudden worse weakness, new falls with injury, severe headache/fever with pump in place, new loss of bladder control, severe sedation or confusion after a new medicine, signs of intrathecal baclofen overdose/withdrawal (sleepiness, trouble breathing, high fever, rapid tone change). Soon: gradual increase in stiffness, more falls, bladder or pain not controlled, skin redness over pressure points or braces, low mood or anxiety, or any side effect from spasticity medicines. PubMed

---

Foods to favor and to limit

Eat more:

1. colorful vegetables and fruits,
2. legumes,
3. whole grains,
4. lean proteins (fish/poultry),
5. oily fish 2×/week for omega-3s,
6. nuts/seeds,
7. low-fat dairy or fortified alternatives (vitamin D, calcium), (8) olive oil,
8. adequate water, (10) spices like turmeric/ginger in cooking. These patterns help weight, lipids, inflammation, and energy. MDPI+1

Limit:

1. sugary drinks,
2. ultra-processed snacks,
3. trans-fats,
4. excess saturated fat,
5. heavy alcohol (worsens balance),
6. very high salt (BP),
7. large late-night meals (sleep),
8. energy drinks/caffeine spikes (spasm trigger for some),
9. crash diets,
10. grapefruit if taking interacting meds (ask pharmacist). NICE

---

Frequently Asked Questions

1) Is SPG76 curable?
No disease-modifying therapy yet; care focuses on rehab, spasticity control, and safety. Research on calpain-selective inhibitors and gene strategies is ongoing. Wiley Online Library+1

2) Will I need a wheelchair?
Many people walk for years with therapy, braces, or FES. Some eventually need a cane/walker or wheelchair for distance. Early rehab delays loss of mobility. SAGE Journals

3) Can therapy really help if it’s genetic?
Yes. Therapy does not change genes, but it preserves function, prevents contractures, and lowers fall risk. SAGE Journals

4) Which medicine works best for spasticity?
Often baclofen or tizanidine first; add botulinum toxin for focal muscles; IT baclofen for severe cases. The plan is individualized. NICE+2FDA Access Data+2

5) Are benzodiazepines safe long term?
They can help short-term but cause sedation, imbalance, and dependence. Use the lowest dose for the shortest time. FDA Access Data

6) Do supplements cure HSP?
No. They may support overall health (e.g., vitamin D, omega-3s, CoQ10) but are not a treatment for CAPN1 disease. PubMed+1

7) Is SDR surgery for adults like me?
Sometimes, in very selected cases with refractory tone. It can lower spasticity but has risks; discuss at a specialized center. PMC

8) What about stem cells?
Not proven for HSP; consider only in clinical trials due to uncertain benefit and risks. PMC

9) Can dalfampridine help walking?
It’s FDA-approved to improve walking in MS and may be considered off-label in other UMN disorders after risk review (seizure risk). FDA Access Data

10) Why do I get bladder urgency?
Upper motor neuron changes can over-activate bladder muscles. Antimuscarinics or mirabegron plus bladder training can help. FDA Access Data+1

11) How often should I do home exercises?
Usually daily stretching and 2–3 days/week strengthening, adjusted to fatigue and pain. SAGE Journals

12) Can FES replace my brace?
Sometimes. Evidence shows FES can improve foot-drop; long-term choice depends on comfort, skin, and goals. PubMed

13) What causes days when stiffness suddenly worsens?
Triggers include infection, stress, poor sleep, dehydration, and missed meds. Managing triggers helps. PMC

14) Is pain part of HSP?
Yes—muscle cramps, joint overload, or neuropathic pain can occur; treatment combines therapy, targeted meds, and pacing. PMC

15) Where should I be treated?
A multidisciplinary neuro-rehab clinic (neurology, physiatry, PT/OT, urology) familiar with spasticity and HSP gives the best outcomes. PMC

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 13, 2025.